68

Nanjing Medlander Medical Technology Co. Ltd. A

688273 · SHG · Healthcare / Medical Devices

25.86CNY-0.65 (-2.45%)

Price History

Full chart

Market Stats

Previous Close26.51
Open26.59
Day Range25.83 – 27.03
52-Week Range26.19 – 60.51
Volume780.02K
Market Cap2.95B
P/E (TTM)38.31
Forward P/E0.00
EPS0.77
Dividend Yield4.07%
Beta0.47
50-Day Avg29.63
200-Day Avg39.98

About

Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally. It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation and anti-aging product, and sports rehabilitation products, as well as consumables and IT products, such as vaginal electrodes, rectal electrodes, and vaginal probes. The company also provides electronic colposcopes, biofeedback stimulation devices, high-frequency electrocautery devices, ultrasonic uterine involution devices, and electro-ultrasound therapy devices; and finger joint rehabilitation assessment systems, portable hand function rehabilitation assessment systems, hand function magnetic stimulation systems, transcranial magnetic stimulation systems, biofeedback devices, and portable biofeedback devices. In addition, it provides pelvic floor muscle rehabilitation devices and power recliner. It serves clients in gynecology, obstetrics, rehabilitation, proctology, postpartum recovery centers, and urology areas. The company was founded in 2013 and is headquartered in Nanjing, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Ruijia Yang
  • Employees559
  • HeadquartersNorth Building A2, Nanjing, China, 210012, China
  • Websitehttps://medlander.com

Leadership

  • Mr. Ruijia YangChairman of the Board & GM · b. 1978
  • Ms. Ning XuCFO & Accounting Supervisor · b. 1986
  • Mr. Bin ChenDirector & Deputy GM · b. 1976
  • Mr. Zhihuai ShiDeputy GM & Director · b. 1975
  • Ms. Jiangning ChenDeputy GM & Board Secretary · b. 1977
  • Mr. Wang WangDeputy General Manager · b. 1982
  • Mr. Honglin TuDeputy GM & Director · b. 1980
  • Ms. Lu FanCore Technical personnel · b. 1986

Financials

Income Statement

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue336.52M341.64M376.89M340.82M424.55M431.59M
Growth (%)-+1.52%+10.32%-9.57%+24.57%+1.66%
Cost of Revenue80.20M92.49M118.53M98.47M119.04M128.60M
Gross Profit256.32M249.15M258.36M242.36M305.51M303.00M
Gross Margin76.17%72.93%68.55%71.11%71.96%70.20%
Operating Expense120.96M124.09M126.16M167.93M192.97M201.23M
Operating Income135.36M125.06M132.20M74.43M112.54M101.77M
Operating Margin40.22%36.60%35.08%21.84%26.51%23.58%
EBITDA--160.67M119.71M152.87M137.35M
EBITDA Margin--42.63%35.12%36.01%31.82%
Net Income121.93M118.38M121.68M89.82M101.58M102.63M
Net Income Margin36.23%34.65%32.29%26.35%23.93%23.78%
R&D41.35M37.23M41.34M58.24M57.33M61.27M
R&D as % of Total Revenue12.29%10.90%10.97%17.09%13.50%14.20%
Interest Expense444.14K152.71K300.94K380.94K1.06M1.39M
Interest Expense % of Total Revenue0.13%0.04%0.08%0.11%0.25%0.32%

Balance Sheet

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets336.15M488.74M1.51B1.53B1.55B1.63B
Total Liabilities88.69M116.01M141.96M158.60M199.66M259.67M
Total Equity240.42M363.50M1.35B1.35B1.31B1.35B
Cash149.82M272.62M1.18B991.63M461.56M816.45M

Cash Flow

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow131.10M148.60M126.67M136.91M122.51M105.43M
Capital Expenditure25.91M14.58M54.26M75.15M129.71M118.15M
Free Cash Flow105.18M134.01M72.41M61.76M-7.20M-12.73M
Dividends Paid54.12M32.62K50.00M82.22M98.90M68.70M
FCF to OCF80.23%90.19%57.16%45.11%-5.88%-12.07%
Dividend Paid to FCF51.46%0.02%69.05%133.12%-1373.90%-539.82%

Earnings

Report DateMar 1, 2023Apr 26, 2023
EPS Estimate--
EPS Actual0.240.32
Surprise--
Timing--

Key Statistics & Ratios

Market Cap2.95B
Enterprise Value2.32B
Trailing P/E38.31
Forward P/E0.00
Price / Sales7.70
Price / Book2.25
EPS0.77
Book Value13.65
Revenue (TTM)383.30M
Gross Profit (TTM)260.19M
EBITDA69.47M
Profit Margin19.68%
Operating Margin8.02%
Return on Equity5.17%
Return on Assets1.83%
Shares Outstanding100.00M
Shares Float31.57M
Beta0.47
Dividend Yield4.07%
Dividend Rate1.20
Payout Ratio103.69%

Dividends

20261×
0.50May 26, 2026
20252×
0.30Nov 27, 20250.40Jun 17, 2025
20242×
0.40Oct 8, 20240.60Jun 25, 2024
20231×
0.80May 31, 2023
20221×
0.50Nov 24, 2022